Titre
Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT).
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Helmberger, T.
Auteure/Auteur
Golfieri, R.
Auteure/Auteur
Pech, M.
Auteure/Auteur
Pfammatter, T.
Auteure/Auteur
Arnold, D.
Auteure/Auteur
Cianni, R.
Auteure/Auteur
Maleux, G.
Auteure/Auteur
Munneke, G.
Auteure/Auteur
Pellerin, O.
Auteure/Auteur
Peynircioglu, B.
Auteure/Auteur
Sangro, B.
Auteure/Auteur
Schaefer, N.
Auteure/Auteur
de Jong, N.
Auteure/Auteur
Bilbao, J.I.
Auteure/Auteur
Contributrices/contributeurs
Pelage, J.P.
Manas, D.M.
Kolligs, F.T.
Ezziddin, S.
Peters, R.
Albrecht, T.
D'Archambeau, O.
Balli, T.
Bilgic, S.
Bloom, A.
Cioni, R.
Fischbach, R.
Flamen, P.
Gerard, L.
Grözinger, G.
Katoh, M.
Koehler, M.
Kröger, J.R.
Kuhl, C.
Orsi, F.
Ozgun, M.
Reimer, P.
Ronot, M.
Schmid, A.
Vit, A.
Groupes de travail
On behalf of the CIRT Steering Committee
On behalf of the CIRT Principal Investigators
Liens vers les personnes
Liens vers les unités
ISSN
1432-086X
Statut éditorial
Publié
Date de publication
2021-01
Volume
44
Numéro
1
Première page
21
Dernière page/numéro d’article
35
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
To address the lack of prospective data on the real-life clinical application of trans-arterial radioembolization (TARE) in Europe, the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) initiated the prospective observational study CIRSE Registry for SIR-Spheres® Therapy (CIRT).
Patients were enrolled from 1 January 2015 till 31 December 2017. Eligible patients were adult patients treated with TARE with Y90 resin microspheres for primary or metastatic liver tumours. Patients were followed up for 24 months after treatment, whereas data on the clinical context of TARE, overall survival (OS) and safety were collected.
Totally, 1027 patients were analysed. 68.2% of the intention of treatment was palliative. Up to half of the patients received systemic therapy and/or locoregional treatments prior to TARE (53.1%; 38.3%). Median overall survival (OS) was reported per cohort and was 16.5 months (95% confidence interval (CI) 14.2-19.3) for hepatocellular carcinoma, 14.6 months (95% CI 10.9-17.9) for intrahepatic cholangiocarcinoma. For liver metastases, median OS for colorectal cancer was 9.8 months (95% CI 8.3-12.9), 5.6 months for pancreatic cancer (95% CI 4.1-6.6), 10.6 months (95% CI 7.3-14.4) for breast cancer, 14.6 months (95% CI 7.3-21.4) for melanoma and 33.1 months (95% CI 22.1-nr) for neuroendocrine tumours. Statistically significant prognostic factors in terms of OS include the presence of ascites, cirrhosis, extra-hepatic disease, patient performance status (Eastern Cooperative Oncology Group), number of chemotherapy lines prior to TARE and tumour burden. Thirty-day mortality rate was 1.0%. 2.5% experienced adverse events grade 3 or 4 within 30 days after TARE.
In the real-life clinical setting, TARE is largely considered to be a part of a palliative treatment strategy across indications and provides an excellent safety profile.
Level 3.
ClinicalTrials.gov NCT02305459.
Patients were enrolled from 1 January 2015 till 31 December 2017. Eligible patients were adult patients treated with TARE with Y90 resin microspheres for primary or metastatic liver tumours. Patients were followed up for 24 months after treatment, whereas data on the clinical context of TARE, overall survival (OS) and safety were collected.
Totally, 1027 patients were analysed. 68.2% of the intention of treatment was palliative. Up to half of the patients received systemic therapy and/or locoregional treatments prior to TARE (53.1%; 38.3%). Median overall survival (OS) was reported per cohort and was 16.5 months (95% confidence interval (CI) 14.2-19.3) for hepatocellular carcinoma, 14.6 months (95% CI 10.9-17.9) for intrahepatic cholangiocarcinoma. For liver metastases, median OS for colorectal cancer was 9.8 months (95% CI 8.3-12.9), 5.6 months for pancreatic cancer (95% CI 4.1-6.6), 10.6 months (95% CI 7.3-14.4) for breast cancer, 14.6 months (95% CI 7.3-21.4) for melanoma and 33.1 months (95% CI 22.1-nr) for neuroendocrine tumours. Statistically significant prognostic factors in terms of OS include the presence of ascites, cirrhosis, extra-hepatic disease, patient performance status (Eastern Cooperative Oncology Group), number of chemotherapy lines prior to TARE and tumour burden. Thirty-day mortality rate was 1.0%. 2.5% experienced adverse events grade 3 or 4 within 30 days after TARE.
In the real-life clinical setting, TARE is largely considered to be a part of a palliative treatment strategy across indications and provides an excellent safety profile.
Level 3.
ClinicalTrials.gov NCT02305459.
PID Serval
serval:BIB_7DC74721E162
PMID
Open Access
Oui
Date de création
2020-09-28T07:30:30.244Z
Date de création dans IRIS
2025-05-21T02:36:17Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
32959085_BIB_7DC74721E162.pdf
Version du manuscrit
published
Licence
https://creativecommons.org/licenses/by/4.0
Taille
678.35 KB
Format
Adobe PDF
PID Serval
serval:BIB_7DC74721E162.P001
URN
urn:nbn:ch:serval-BIB_7DC74721E1620
Somme de contrôle
(MD5):84619195be53f85e0f75ff30361a9755